Back to results
US 2022/0034896 A1Published application
Methods for quantitative analysis of one or more biomarkers
AssigneeThe Research Foundation for The State University of New York
InventorNathaniel Cady
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to apparatuses and methods for detecting the amount and/or type of one or more analytes-of-interests such as biomarkers in a sample. In embodiments, the disclosure includes a method for determining a humoral response due to the presence of a target infectious agent or vaccine. In embodiments, detecting emission light from one or more fluorescent complexes is used to determine a type and/or quantity of the plurality of biomarkers.
Claims20
A method for determining a humoral response due to a presence of a target infectious agent or vaccine, comprising:
- capturing one or more biomarkers on a substrate that binds a plurality of biomarkers to one or more binding sites, wherein one or more binding sites bind one or more biomarkers, and wherein when one or more biomarkers are present, forming one or more bound biomarkers-of-interest;
- contacting the one or more bound biomarkers-of-interest with one or more fluorescent binding partners to form one or more fluorescent complexes;
- contacting the substrate with a source of collimated, polarized light, wherein the source of collimated polarized light is configured to emit light at a predetermined wavelength appropriate for transferring energy to a plurality of surface plasmons and excite fluorescence of the one or more fluorescent complexes;
- detecting emission light of the one or more fluorescent complexes;
- and
- determining a type and/or quantity of the plurality of biomarkers.
3 more elements
An apparatus for quantitative analysis of a plurality of biomarkers contained in a sample, comprising:
- a substrate comprising a plurality of binding sites, one or more of the plurality of binding sites comprises one or more predetermined antigens configured to bind to one or more predetermined biomarkers-of-interest and form one or more bound biomarkers-of-interest when biomarkers-of-interest are flowed over the substrate, and wherein the biomarkers-of-interest, when present, are bind one or more fluorescent binding partners to form one or more fluorescent complexes;
- and
- a grating-coupled fluorescent plasmonic (GC-FP) detection platform, wherein the platform contacts the substrate with a source of collimated, polarized light, wherein the source of collimated polarized light emits light at a predetermined wavelength appropriate for transferring energy to a plurality of surface plasmons and excite fluorescence of the one or more fluorescent complexes, wherein the one or more biomarkers-of-interest are selected from immunoglobulins comprising one or more of immunoglobulin G (IgG) directed against SARS-CoV-2, a SARS-CoV-2 variant, and/or a COVID 19 vaccine, immunoglobulin M (IgM) directed against SARS-CoV-2, a SARS-CoV-2 variant, and/or a COVID 19 vaccine, immunoglobulin A (IgA) directed against SARS-CoV-2, a SARS-CoV-2 variant, and/or a COVID 19 vaccine, or isotypes or combinations thereof.
A method for determining a humoral response due to a presence of a target infectious agent or vaccine, comprising:
- detecting in a biological sample of a subject at least one target antibody that is susceptible of being produced by the subject when the subject is vaccinated or infected by a target infectious agent, wherein the method comprises:
- capturing the at least one target antibody on a substrate that binds the at least one target antibody to a plurality of binding sites, wherein one or more binding sites bind one or more target antibodies, and wherein when one or more target antibodies are present forming one or more bound biomarkers-of-interest;
- contacting the one or more bound biomarkers-of-interest with one or more fluorescent binding partners to form one or more fluorescent complexes;
- contacting the substrate with a source of collimated, polarized light, wherein the source of collimated polarized light emits light at a predetermined wavelength appropriate for transferring energy to a plurality of surface plasmons and excite fluorescence of the one or more fluorescent complexes;
- detecting emission light of the one or more fluorescent complexes;
- and
- determining a type and/or quantity of the at least one target antibody, wherein the at least one target antibody is selected from immunoglobulins comprising one or more of immunoglobulin G (IgG) directed against SARS-CoV-2, a SARS-CoV-2 variant, and/or a COVID 19 vaccine, immunoglobulin M (IgM) directed against SARS-CoV-2, a SARS-CoV-2 variant, and/or a COVID 19 vaccine, immunoglobulin A (IgA) directed against SARS-CoV-2, a SARS-CoV-2 variant, and/or a COVID 19 vaccine, or isotypes or combinations thereof.
4 more elements
Dependencies are inferred from the claim text.